research use only
Cat.No.S8975
| Related Targets | Proteasome E1 Activating DUB SUMO p97 E2 conjugating |
|---|---|
| Other E3 Ligase Inhibitors | Iberdomide (CC-220) Skp2 inhibitor C1 (SKPin C1) Apcin Avadomide (CC-122) PRT4165 VL285 SZL P1-41 CC-90009 VH298 Homo-PROTAC cereblon degrader 1 |
|
In vitro |
DMSO
: 100 mg/mL
(176.17 mM)
Water : Insoluble Ethanol : Insoluble |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Molecular Weight | 567.61 | Formula | C32H30FN5O4 |
Storage (From the date of receipt) | 3 years -20°C powder |
|---|---|---|---|---|---|
| CAS No. | 2259648-80-9 | -- | Storage of Stock Solutions |
|
|
| Synonyms | N/A | SMILES | C1CC(=O)NC(=O)C1N2CC3=C(C2=O)C=CC=C3OCC4=CC=C(C=C4)CN5CCN(CC5)C6=C(C=C(C=C6)C#N)F | ||
Read more about storage stability stock solution CAS number SMILES
| Targets/IC50/Ki |
Cereblon
|
|---|---|
| In vitro |
Mezigdomide (CC-92480) has a unique and rapid degradation profile: it enhances the efficiency to drive the formation of the protein−protein interaction between Aiolos and cereblon, inducing targeted docking to the CRL4-CRBN E3 ubiquitin ligase complex. The CC-92480-dependent binding of Aiolos/Ikaros to CRBN leads to polyubiquitination and ultimately proteasome-mediated degradation of protein. Rapid and extensive loss of Aiolos/Ikaros in sensitive cells, such as multiple myeloma cells, results in apoptosis and subsequent cell death. |
| In vivo |
Mezigdomide (CC-92480) is evaluated in efficacy models to assess tumor growth inhibition in tumor bearing mice. When tumors reaches approximately 150 mm3, mice are randomized and treated once daily (q.d.) orally with vehicle control or various dosage strengths of this compound. Both the 3 and 10 mg/kg doses give near maximal response in this model, while the lowest dose tested (1 mg/kg) shows 75% reduction in tumor volume by the end of the study. |
References |
(data from https://clinicaltrials.gov, updated on 2026-07-21)
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT06892522 | RECRUITING | Multiple Myeloma |
AbbVie |
2025-06-30 | PHASE1; PHASE2 |
| NCT07348393 | NOT_YET_RECRUITING | Relapsed or Refractory Multiple Myeloma (RRMM) |
Assistance Publique - Hôpitaux de Paris |
2026-02 | PHASE2 |
| NCT07356154 | RECRUITING | Leukemia; Acute Leukemia; Relapse Leukemia; Refractory Leukemia; Refractory Acute Leukemia; Acute Myeloid Leukemia; Acute Lymphoblastic Leukemia; Mixed Phenotype Acute Leukemia |
Memorial Sloan Kettering Cancer Center |
2026-01-16 | PHASE1; PHASE2 |
| NCT07105059 | RECRUITING | Multiple Myeloma |
Memorial Sloan Kettering Cancer Center |
2025-08-08 | PHASE1 |
| NCT06121843 | RECRUITING | Multiple Myeloma |
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company |
2024-02-22 | PHASE1 |
| NCT07612787 | NOT_YET_RECRUITING | Myeloma Multiple |
Centre Hospitalier Universitaire de Saint Etienne |
2026-06-01 | PHASE1; PHASE2 |
Read more about Clinical Trials
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.